Fibrates are synthetic PPARα agonists that are clinically used to treat dyslipidemia (11), and we investigated whether fenofibrate could ameliorate NAFLD in Pemt−/− mice. Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.